Welcome to our dedicated page for Concentrix SEC filings (Ticker: CNXC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Concentrix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Concentrix's regulatory disclosures and financial reporting.
Concentrix (CNXC) reported an insider share purchase by its President & CEO, who is also a Director. On 10/10/2025, the executive bought 1,000 shares of common stock at $45.35 per share (transaction code P). Following the transaction, the executive beneficially owns 305,345 shares, held directly.
Christopher A. Caldwell, President and CEO and Director of Concentrix Corp (CNXC), reported a sale of common stock on 10/07/2025. The filing shows 390 shares were sold at $47.76, leaving Mr. Caldwell with 304,345 shares held directly after the transaction. The Form 4 was signed by an attorney-in-fact on 10/09/2025. No options or derivative transactions were reported.
Jane Fogarty, Executive Vice President, Legal at Concentrix Corp (CNXC), reported a sale of company stock on 10/05/2025. The Form 4 shows 126 shares sold at a price of $48.26 per share, leaving 19,131 shares beneficially owned directly after the transaction. The filing is signed by an attorney-in-fact on 10/07/2025.
Concentrix Corporation presents interim unaudited consolidated financial statements prepared in accordance with SEC rules and GAAP with normal recurring adjustments. The filing discloses 69,120 and 68,849 shares issued as of August 31, 2025 and November 30, 2024, and 62,209 and 64,238 shares outstanding on those dates. The Company reports accounts receivable activity under factoring programs, with $127,000 outstanding at August 31, 2025 and sales of $328,000 during the three months ended August 31, 2024. In connection with the Webhelp acquisition, Concentrix recorded cross-currency interest rate swaps on $500,000 of senior notes to synthetically convert $250,000 of 2026 notes and $250,000 of 2028 notes into euro-based debt at weighted rates of 5.12% and 5.18%, respectively. Term loan principal outstanding decreased to $1,350,000 at August 31, 2025 from $1,500,000 on November 30, 2024, after voluntary prepayments of $150,000 in the nine months. The company amended its credit facilities (Restated Credit Agreement) providing multiple term and delayed-draw facilities and a $1.1 billion revolving credit capacity. The Securitization Facility commitment was increased to $700,000. Concentrix repurchased 2,247 shares for $112,774 in the nine months ended August 31, 2025 and reports approximately $495,402 remaining under its repurchase authorization. Pension plans were underfunded by $81,974 at August 31, 2025. The Company states it was in compliance with covenant requirements as of August 31, 2025.
Concentrix Corp director and President/CEO Christopher A. Caldwell reported three transactions on 09/30/2025. He acquired 1,000 shares of Common Stock at $47.435, exercised 9,363 employee stock options with an exercise price of $44.52, and had 8,990 shares withheld to satisfy the option exercise price and taxes. After these transactions the reported beneficial ownership totals shown on the form include 313,725 and similar post-transaction balances for direct holdings.
Twomey Cormac J, Executive Vice President, Global Ops & Delivery at Concentrix Corp (CNXC), reported a sale of 500 shares of the issuer's common stock on 09/30/2025 at a price of $47.08 per share. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan established on January 28, 2025. After the reported transaction the reporting person beneficially owns 36,130 shares, held directly. The Form 4 was filed as a single-person filing and bears an attorney-in-fact signature dated 10/02/2025.
Form 144 notice for Concentrix Corp (CNXC) reports a proposed sale of 500 restricted shares by the named person through Morgan Stanley Smith Barney, with an aggregate market value of $23,540 and an approximate sale date of 09/30/2025 on NASDAQ. The shares were originally acquired as restricted stock on 06/01/2021 from the issuer. The filer also reported two recent sales by the same person in the past three months: 500 shares sold on 07/30/2025 for $28,955 and 500 shares sold on 08/29/2025 for $25,125. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Concentrix Corporation filed a current report stating that it has released its financial results for the third quarter ended August 31, 2025. The company issued a press release on September 25, 2025 to share details about its operations and financial condition for the period.
The press release is included as an exhibit to the report and is incorporated by reference into the results section, giving investors and analysts a central source for the company’s latest quarterly performance information.
Concentrix Corp (CNXC) reporting person Cormac J. Twomey, EVP Global Ops & Delivery, reported a sale of 500 shares of Common Stock on 08/29/2025 at a price of $50.25 per share. After the sale, the reporting person beneficially owned 36,630 shares. The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan established on January 28, 2025.
The Form 4 is signed by an attorney-in-fact and indicates this was a planned disposition rather than an ad hoc trade. No derivative transactions or other changes in holdings are reported.
Form 144 notice shows a proposed insider sale of 500 common shares scheduled for 08/29/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $25,125. The shares were originally acquired as restricted stock on 06/01/2021 from the issuer. The filing reports total shares outstanding of 63,025,120, and lists three recent sales by the same seller of 500 shares each on 05/30/2025, 06/30/2025 and 07/30/2025 with gross proceeds shown. The seller is named as Cormac Twomey with an address provided. The filing includes the standard representation that the seller is unaware of undisclosed material adverse information.
Note: The issuer name and SEC file number are not provided in the supplied content.